MiniMed Group (NASDAQ:MMED) Reaches New 12-Month High on Analyst Upgrade

MiniMed Group Inc (NASDAQ:MMED) hit a new 52-week high during trading on Tuesday after Citigroup raised their price target on the stock from $23.00 to $26.00. Citigroup currently has a buy rating on the stock. MiniMed Group traded as high as $21.86 and last traded at $21.0940, with a volume of 387936 shares. The stock had previously closed at $20.26.

Other analysts also recently issued research reports about the company. Piper Sandler restated a “neutral” rating and issued a $16.00 target price on shares of MiniMed Group in a research report on Thursday, June 4th. Wells Fargo & Company increased their target price on shares of MiniMed Group from $22.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday. Benchmark reissued a “buy” rating on shares of MiniMed Group in a research note on Thursday, June 4th. Mizuho raised their price objective on MiniMed Group from $21.00 to $26.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, UBS Group boosted their target price on MiniMed Group from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $23.62.

MiniMed Group News Roundup

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: MiniMed reported fiscal Q1 2027 net sales of approximately $843 million, up 17% year over year, with organic U.S. growth accelerating to 13% and international sales rising 18% as reported. The company also raised its fiscal-year organic revenue-growth guidance. MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
• Positive Sentiment: Management highlighted progress across its product pipeline, including an FDA submission for MiniMed Fit™, CE Mark approval for MiniMed Flex™, completion of the Vivera™ FCL U.S. pivotal trial enrollment and IDE approval for a next-generation extended-wear sensor. MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
• Positive Sentiment: Several firms raised their targets following the sales report. Citigroup and Wells Fargo moved to $26, while UBS raised its target to $28 and maintained a “buy” rating. Mizuho also set a $26 target with an “outperform” rating; Bank of America and BTIG raised their targets to $28 and reiterated “buy” ratings. These revisions signal improving analyst confidence in MiniMed’s growth outlook. These Analysts Boost Their Forecasts On MiniMed Group Following Q1 Sales Results
• Neutral Sentiment: The reported brokerage consensus target of $21.62 remains below the latest trading level, suggesting that some analysts’ estimates may not yet reflect the newest quarterly results and upgrades. MiniMed Group Receives Consensus Target Price from Brokerages

Institutional Trading of MiniMed Group

Several large investors have recently modified their holdings of MMED. California State Teachers Retirement System purchased a new position in MiniMed Group during the 2nd quarter valued at about $89,000. Legal & General Group Plc purchased a new position in shares of MiniMed Group during the second quarter valued at approximately $91,000. The Manufacturers Life Insurance Company purchased a new stake in MiniMed Group in the second quarter worth $185,000. Punch & Associates Investment Management Inc. bought a new stake in MiniMed Group in the second quarter valued at $292,000. Finally, Washington Growth Strategies LLC bought a new position in MiniMed Group in the 2nd quarter worth $397,000.

MiniMed Group Stock Up 6.0%

The business has a fifty day simple moving average of $17.84. The company has a market cap of $6.68 billion and a price-to-earnings ratio of -34.94.

MiniMed Group (NASDAQ:MMED) last announced its quarterly earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.46). The company had revenue of $837.00 million for the quarter. The business’s revenue was up 15.6% on a year-over-year basis. Equities research analysts expect that MiniMed Group Inc will post 0.66 EPS for the current year.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.